1. Home
  2. ICUI vs SRRK Comparison

ICUI vs SRRK Comparison

Compare ICUI & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ICUI
  • SRRK
  • Stock Information
  • Founded
  • ICUI 1984
  • SRRK 2012
  • Country
  • ICUI United States
  • SRRK United States
  • Employees
  • ICUI N/A
  • SRRK N/A
  • Industry
  • ICUI Medical/Dental Instruments
  • SRRK Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ICUI Health Care
  • SRRK Health Care
  • Exchange
  • ICUI Nasdaq
  • SRRK Nasdaq
  • Market Cap
  • ICUI 3.4B
  • SRRK 3.2B
  • IPO Year
  • ICUI 1992
  • SRRK 2018
  • Fundamental
  • Price
  • ICUI $127.74
  • SRRK $34.04
  • Analyst Decision
  • ICUI Strong Buy
  • SRRK Strong Buy
  • Analyst Count
  • ICUI 5
  • SRRK 6
  • Target Price
  • ICUI $196.75
  • SRRK $42.17
  • AVG Volume (30 Days)
  • ICUI 198.1K
  • SRRK 1.3M
  • Earning Date
  • ICUI 08-06-2025
  • SRRK 08-07-2025
  • Dividend Yield
  • ICUI N/A
  • SRRK N/A
  • EPS Growth
  • ICUI N/A
  • SRRK N/A
  • EPS
  • ICUI N/A
  • SRRK N/A
  • Revenue
  • ICUI $2,420,093,000.00
  • SRRK N/A
  • Revenue This Year
  • ICUI N/A
  • SRRK N/A
  • Revenue Next Year
  • ICUI N/A
  • SRRK $502.60
  • P/E Ratio
  • ICUI N/A
  • SRRK N/A
  • Revenue Growth
  • ICUI 7.22
  • SRRK N/A
  • 52 Week Low
  • ICUI $111.97
  • SRRK $6.76
  • 52 Week High
  • ICUI $196.26
  • SRRK $46.98
  • Technical
  • Relative Strength Index (RSI)
  • ICUI 39.54
  • SRRK 55.54
  • Support Level
  • ICUI $125.78
  • SRRK $30.97
  • Resistance Level
  • ICUI $133.85
  • SRRK $37.00
  • Average True Range (ATR)
  • ICUI 3.34
  • SRRK 2.05
  • MACD
  • ICUI -0.32
  • SRRK 0.23
  • Stochastic Oscillator
  • ICUI 15.71
  • SRRK 65.40

About ICUI ICU Medical Inc.

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.

About SRRK Scholar Rock Holding Corporation

Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.

Share on Social Networks: